Indivior Prices Upsized $450M Convertible Notes at 35% Premium, Repays Debt & Repurchases Shares

summarizeSummary

Indivior Pharmaceuticals priced an upsized $450 million offering of convertible senior notes with a 35% conversion premium, using proceeds to repay debt and repurchase shares.

check_boxKey Events

• Upsized Convertible Notes Offering Priced

  Indivior priced an upsized offering of $450 million in 0.625% convertible senior notes due 2031, up from the initially proposed $400 million. Initial purchasers have a 30-day option to purchase an additional $50 million principal amount of notes.

• Premium Conversion Price Set

  The notes feature an initial conversion price of approximately $41.66 per share, representing a 35.0% premium over the stock's last reported sale price on March 12, 2026.

• Strategic Debt Repayment

  Approximately $239 million of the net proceeds, combined with $102 million of cash on hand, will be used to repay borrowings under the company's term loan and revolving credit facility.

• Concurrent Share Repurchase

  The company will use $75 million of the net proceeds to repurchase approximately 2.4 million shares of its common stock concurrently with the pricing of the offering.

auto_awesomeAnalysis

This 8-K finalizes the terms and pricing of the previously announced convertible senior notes offering, which was upsized to $450 million. The offering is significant, representing over 11% of the company's market capitalization. Key positive aspects include the 35% premium on the conversion price, indicating investor confidence in future stock appreciation, and the strategic use of proceeds. A substantial portion will repay existing debt, strengthening the balance sheet. Additionally, the concurrent repurchase of $75 million in common stock helps mitigate potential dilution from the convertible notes and signals management's confidence. This financing provides significant capital while managing shareholder impact effectively.